Last edition
News about "Mitsubishi Tanabe Pharma America"
MTPA Signs Deal with Dewpoint to Advance Small Molecule Condensate Modulator
The collaboration focuses on developing a novel TDP-43 small molecule condensate modulator (c-mod) for amyotrophic lateral sclerosis (ALS), furthering MTPC's commitment to advancing innovation in ALS and central nervous system (CNS) diseases.
Mitsubishi Tanabe Pharma America | 19/12/2024 | By Aishwarya
MTPA Presents Healthcare Resource Utilization Data in RADICAVA ORS at AMCP 2024
Mitsubishi Tanabe Pharma America, Inc. (MTPA) has recently presented one abstract on amyotrophic lateral sclerosis (ALS) at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting.
Mitsubishi Tanabe Pharma America | 16/04/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy